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Abstract
Background: Fluorine-18 dihydrotetrabenazine [DTBZ] analogues, which selectively target the vesicular
monoamine transporter 2 [VMAT2], have been extensively studied for in vivo quantification of beta cell mass by
positron-emission tomography [PET]. This study describes a novel deuterated radioligand [
18F]fluoroethyl [FE]-DTBZ-
d4, aimed to increase the stability against in vivo defluorination previously observed for [
18F]FE-DTBZ.
Methods: [
18F]FE-DTBZ-d4 was synthesized by alkylation of 9-O-desmethyl-(+)-DTBZ precursor with deuterated [
18F]
FE bromide ([
18F]FCD2CD2Br). Radioligand binding potential [BP] was assessed by an in vitro saturation homogenate
binding assay using human endocrine and exocrine pancreatic tissues. In vivo pharmacokinetics and
pharmacodynamics [PK/PD] was studied in a porcine model by PET/computed tomography, and the rate of
defluorination was quantified by compartmental modeling.
Results: [
18F]FE-DTBZ-d4 was produced in reproducible good radiochemical yield in 100 ± 20 min. Radiochemical
purity of the formulated product was > 98% for up to 5 h with specific radioactivities that ranged from 192 to 529
GBq/μmol at the end of the synthesis. The in vitro BP for VMAT2 in the islet tissue was 27.0 ± 8.8, and for the
exocrine tissue, 1.7 ± 1.0. The rate of in vivo defluorination was decreased significantly (kdefluorination = 0.0016 ±
0.0007 min
-1) compared to the non-deuterated analogue (kdefluorination = 0.012 ± 0.002 min
-1), resulting in a six fold
increase in half-life stability.
Conclusions: [
18F]FE-DTBZ-d4 has similar PK and PD properties for VMAT2 imaging as its non-deuterated analogue
[
18F]FE-DTBZ in addition to gaining significantly increased stability against defluorination. [
18F]FE-DTBZ-d4 is a prime
candidate for future preclinical and clinical studies on focal clusters of beta cells, such as in intramuscular islet
grafts.
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Introduction
Dihydrotetrabenazine [DTBZ], derived from the neu-
roactive pharmaceutical tetrabenazine, is a ligand for the
vesicular monoamine transporter 2 [VMAT2] which is
expressed primarily in cells associated with the regula-
tion of neurotransmission. It is especially associated
with the dopaminergic system, and [
11C]DTBZ has
previously been used to study, for example, aspects of
dementia [1] and Parkinson’s disease [2] in the clinic.
High VMAT2 expression has also been found in insu-
lin-producing beta cells in the endocrine islets of Lan-
gerhans, but not in the exocrine pancreas [3], and the
regional receptor density in the pancreas has therefore
been hypothesized to reflect actual beta cell mass
[BCM].
Several analogues of DTBZ are currently being
explored as putative positron-emission tomography
[PET] tracers for the quantification of BCM, including
[
11C]DTBZ [4-6], [
18F]fluoroethyl [FE]-DTBZ [7], and
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18F]FP-DTBZ [8-10]. Finding an ideal biomarker to
quantify BCM is a big challenge as beta cells are low in
abundance (1% to 2%) and dispersed all over the pan-
creas. [
11C]DTBZ PET studies in humans have shown
initial promising results for the visualization of the pan-
creas [6]. However, recent studies have shown conflict-
ing results, and there is some concern over the
substantial nonspecific uptake of the tracer in the exo-
crine pancreas [4,7]. Using [
11C]DTBZ as a lead com-
pound, recently, [
18F]fluoroalkyl derivatives [11] and
other derivatives of DTBZ analogues [12] with improved
properties over [
11C]DTBZ have been developed. Fluor-
ine-18 has longer half-life (109.8 min) which can extend
the PET experimental time longer than 100 min and
convenient for a long-distance transportation to other
sites not possessing cyclotron facilities.
Our group has previously investigated [
18F]FE-DTBZ
as a BCM imaging agent [7]. We found that the in vitro
binding characteristics of [
18F]FE-DTBZ in the pure
endocrine islet tissue was very favorable, but the rela-
tively high non-displaceable binding to the exocrine
pancreatic tissue was still present despite the increased
lipophilicity compared to [
11C]DTBZ. In vivo studies in
a large animal piglet model revealed highly gradual
accumulation of radioactivity in the joints and bone dur-
ing the PET/computed tomography [PET/CT] examina-
tion performed 90 min after the tracer administration.
Initially, the accumulation of the tracer in the bone was
low and showed a linear increase at the end of the
experiments; the spinal column reached a standardized
uptake value [SUV] of 3.1. By considering the character-
istic of the [
18F]F
- which accumulates readily to the
bone [13], [
18F]FE-DTBZ may be decomposed to [
18F]F
-
by in vivo defluorination. We concluded that although
[
18F]FE-DTBZ has proper pharmacokinetic and pharma-
codynamic [PK/PD] characteristics for the assessment of
VMAT2 distribution in tissues with low non-displace-
able binding, it is still too blunt as an instrument for
pancreatic BCM quantification in its current form.
In this study, we designed an analogue, [
18F]FE-
DTBZ-d4, with the four ethyl hydrogens of [
18F]FE-
DTBZ substituted with deuterium, as a novel radioli-
gand for quantifying BCM (Figure 1). The hypothesis
behind the design of this new radioligand was that the
rate of defluorination of the [
18F]FE moiety would be
reduced through a deuterium isotopic effect since the
carbon-deuterium [C-D] bond is generally stronger to
break than the carbon-hydrogen [C-H] bond. This
approach of reducing the rate of defluorination in vivo
has been previously explored successfully in our group
for the synthesis of the norepinephrine transporter radi-
oligand [
18F]FMeNER-D2 [14] and the cannabinoid sub-
type-1 radioligand [
18F]FMPEP-d2 [15]. Both of these
radiotracers, [
18F]FMeNER-D2 [16] and [
18F]FMPEP-d2
[17], are used clinically today due to their improved
quality by deuteration. Moreover, we can assume that
the high affinity and specificity of [
18F]FE-DTBZ-d4
towards VMAT2 will approximate that of the non-deut-
erated radioligand [
18F]FE-DTBZ since the compounds
are isosteres.
Here, we report the radiosynthesis of [
18F]FE-DTBZ-
d4 and the measured in vitro binding potential [BP] in
the pancreas. To test our hypotheses of reduction in
defluorination and uptake in the bone while maintaining
a similar biological performance (i.e., affinity and specifi-
city to VMAT2), the regional biodistribution of [
18F]FE-
DTBZ-d4 was compared to that of [
18F]FE-DTBZ and
[
18F]F
- in a porcine model by PET/CT.
Materials and methods
General
The precursor 9-O-desmethyl-(+)-DTBZ
[(+)-(2R,3R,11bR)-9-O-desmethyl-a-DTBZ] was pur-
chased from ABX GmbH (Radeberg, Germany). The
nonradioactive standard FE-(+)-DTBZ-d4 [(2R,3R,11bR)-
9-(2-fluoroethoxy)-3-isobutyl-10-methoxy-2,3,4,6,7,11b-
hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol] and the
deuterated 2-bromoethyl tosylate (BrCD2CD2OTs) was
purchased from PharmaSynth AS (Tartu, Estonia). All
other chemicals were obtained from commercial sources
with the highest grade and used without any further
purification. Solid-phase extraction [SPE] cartridges,
Sep-Pak QMA Light and Sep-Pak tC18 Plus, were pur-
chased from Waters Corporation (Milford, MA, USA).
The tC18 Plus cartridge was activated using (1) ethanol
[EtOH] (10 mL) and (2) water (10 mL, 18 MΩ). The
SPE cartridge Sep-Pak QMA Light was activated using
(1) potassium carbonate (K2CO3)s o l u t i o n( 0 . 5M ,1 0
mL) and (2) water (15 mL, 18 MΩ).
Radiosynthesis of [
18F]FE-DTBZ-d4 via 2-[
18F]FE bromide-
d4 ([
18F]FCD2CD2Br, [
18F]FEtBr-d4)
Production of [
18F]F
-
Fluorine-18 fluoride [[
18F]F
-] was produced from a PET-
trace Cyclotron (GEMS, GE, Uppsala, Sweden) using
16.4 MeV protons via the
18O(p,n)
18Fr e a c t i o no n
18O-
enriched water [[
18O]H2O]. [
18F]F
- was isolated from
[
18O]H2O on a preconditioned Sep-Pak QMA Light
anion-exchange cartridge and subsequently eluted from
the cartridge with a solution of K2CO3 (1.8 mg, 13
μmol), Kryptofix 2.2.2 (4,7,13,16,21,24-hexaoxa-1,10-dia-
zabicyclo-[8.8.8]hexacosane-K2.2.2) (9.8 mg, 26 μmol) in
water (85 μL, 18 MΩ), and MeCN (2 mL) to a reaction
vessel (10 mL). The solvents were evaporated at 160°C
for 10 to 15 min under continuous nitrogen flow (70
mL/min) to form a dry complex of [
18F]F
-/K2CO3/
K2.2.2, and the residue was cooled to room temperature
[RT].
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18F]FE bromide-d4 ([
18F]FCD2CD2Br,
[
18F]FEtBr-d4)
2-Bromoethyl tosylate-d4 (15 μL) in o-dichlorobenzene
[o-DCB] (700 μL) was added to the reaction vessel con-
taining dried [
18F]F
-/K2CO3/K2.2.2 complex at RT. The
reaction mixture was heated at 135°C for 10 min to pro-
duce [
18F]FEtBr-d4. The crude [
18F]FEtBr-d4 (boiling
point 71.5°C) was purified by distillation at 80°C under
nitrogen flow (25 mL/min) and trapped in a second
reaction vessel (5 mL) at -15°C containing 9-O-des-
methyl-(+)-DTBZ precursor (2.0 to 2.5 mg, 6.55 to 8.19
μmol) and NaOH (15 μL, 5 M in water) in anhydrous
N,N-dimethylformamide [DMF] (500 μL).
Radiosynthesis of [
18F]FE-DTBZ-d4
The reaction mixture containing [
18F]FEtBr-d4, 9-O-des-
methyl-(+)-DTBZ precursor, and NaOH in DMF was
heated at 110°C for 5 min to produce [
18F]FE-DTBZ-d4.
The crude reaction mixture was diluted with 200 μL
water before injecting into a high-performance liquid
chromatography [HPLC] semi-preparative reverse-phase
μBondapak column (C18, 7.8 Ø × 300 mm, 10 μm,
Waters Corporation) for purification. The column outlet
was connected to an UV absorbance detector (l = 214
nm) in series with a GM tube for radioactivity detection.
Elution with mobile phase CH3CN/10 mM H3PO4
(15:85) at a flow rate of 6 mL/min gave a radioactive
fraction corresponding to pure [
18F]FE-DTBZ-d4 (reten-
tion time = 12 min). The fraction was diluted with
water (50 mL, 18 MΩ), and the resulting mixture was
loaded onto a preconditioned Sep-Pak tC18 Plus car-
tridge. The cartridge was washed with water (10 mL),
and the isolated product, [
18F]FE-DTBZ-d4, was eluted
with 1 mL of EtOH into a sterile vial containing a phos-
phate-buffered saline solution (7 mL).
Quality control
The radiochemical purity, identity, and stability of [
18F]
FE-DTBZ-d4 were determined by analytical HPLC using
a reverse-phase μBondapak column (C18, 3.9 Ø × 300
mm, 10 μm, Waters Corporation) with mobile phase
CH3CN/10 mM H3PO4 (15:85) and a flow rate of 3 mL/
min. The effluent was monitored with an UV absor-
bance detector (l = 214 nm) coupled with a radioactive
detector (b-flow, Beckman Coulter,I n c . ,F u l l e r t o n ,C A ,
USA). The identity of [
18F]FE-DTBZ-d4 was confirmed
by co-injection with the authentic nonradioactive FE-
DTBZ-d4.
Specific radioactivity determination
The specific radioactivity [SRA] of the product was mea-
sured by the same analytical HPLC method for quality
control. SRA was calibrated for UV absorbance (l = 214
nm) response per mass of ligand and calculated as the
radioactivity of the radioligand (in gigabecquerels)
divided by the amount of the associated carrier sub-
stance (in micromoles). Each sample was analyzed three
times and compared to a reference standard analyzed
three times.
LC-MS/MS analysis
Liquid chromatography-mass spectrometry [LC-MS/MS]
analysis of the purified labeled product, [
18F]FE-DTBZ-
d4, and of the reference standard FE-DTBZ-d4 was per-
formed using a Waters Acquity™ Ultra Performance LC
system connected with a Micromass Premier™ Quadru-
pole Time-of-Flight [TOF] mass spectrometer (Waters
Corporation). LC was performed using a Waters Acquity
UPLC™ BEH column (C18, 2.1 Ø × 50 mm, 1.7 μm;
Waters Corporation) kept at 40°C. The mobile phase
consisted of 0.1% formic acid in water (A) and 0.1% for-
mic acid in acetonitrile (B). Samples were analyzed
using a linear gradient (0% to 50% B, from 0 to 4 min;
50% to 100% B, from 4 to 4.50 min and then kept at
100% B to 5 min). The flow rate was 0.5 mL/min. The
MS was operated in positive-mode electrospray ioniza-
tion [ESI], with the following settings: capillary voltage
    (a)                                                            (b)                                                          (c) 
Figure 1 Structures of [
11C]-(+)-DTBZ (a), [
18F]FE-(+)-DTBZ (b), and [
18F]FE-(+)-DTBZ-d4 (c).
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Page 3 of 133.0 kV, cone voltage 45 V, source temperature 120°C,
dissolvation temperature 350°C, and collision-energy
ramp ranging from 20 to 30 eV. [
18F]FE-DTBZ-d4 was
analyzed after radioactive decay without further dilution.
FE-DTBZ-d4 (1 mg/mL) was diluted 200 times with
water.
In vitro homogenate saturation binding
Endocrine (n=4, 80% to 85% islets) or exocrine (n=4)
tissue preparations were isolated from human pancreata
and homogenized in 50 mM tris(hydroxymethyl)amino-
methane [TRIS] by a Polytron PT3000 homogenator
(Kinematica AG, Littau, Switzerland). The tissue homo-
genates (0.5 to 6 mg/mL) were incubated in 1 mL of 50
mM TRIS with different concentrations of tracer around
an expected dissociation constant Kd of 3 nM. The non-
displaceable binding was determined by addition of 10
to 20 μM tetrabenazine (BIOTREND Chemikalien
GmbH, Cologne, Germany).
All samples were incubated at RT for 60 min to reach
an equilibrium and then moved onto a 1.2 μmW h a t -
man filter (Brandel, Gaithersburg, MD, USA; pretreated
with 0.05% polyethylenimine for > 1 h) by a C-48 cell
harvester (Brandel, Gaithersburg, MD, USA). The filter
components associated to each group were pooled and
measured in a well counter (Uppsala Imanet AB, GE
Healthcare, Uppsala, Sweden). Tissue samples and refer-
ences were prepared in triplicates, and filter binding
controls, in duplicates.
Tissue protein content (in milligram protein per sam-
ple) was assessed by a Bio-Rad Protein Assay (Bio-Rad,
Hercules, CA, USA), and absorbance was measured with
an EL808 microplate reader (BioTek, Winooski, VT,
USA). The BP, defined as the ratio between the receptor
density [Bmax] and dissociation constant [Kd], was deter-
mined by nonlinear regression.
PET/CT studies
Male Swedish landrace piglets (n=4, 15 to 17 kg, 11 to
14 weeks old) were anesthetized by Zoletil forte (Virbac,
Carros Cedex, France). The animals were intubated and
placed on a ventilator, and the anesthesia was main-
tained by 2.5% sevofluran. Normoglycemia was con-
firmed by determining blood glucose content (plasma
glucose concentration 4.4 to 7.6 mM). The animal
experiments were approved by the local ethics commit-
tee for animal research and performed in accordance
with local institutional and Swedish national rules and
regulations.
The PET/CT studies were performed using a Discov-
ery ST scanner (General Electric, Milwaukee, WI, USA).
All scans were acquired in 2D mode and reconstructed
by OSEM iterative algorithm. Four piglets were adminis-
tered 3.4 to 16.3 MBq/kg [
18F]FE-DTBZ-d4 as an
intravenous [i.v.] bolus, and the biodistribution as well
as the kinetics of the tracer in the abdomen was studied
with a dynamic sequence over 90 min (the head first,
prone, 4 frames × 30 s, 3 × 1 min, 5 × 3 min and 14 ×
5 min). Arterial blood samples were acquired during the
first 90 min, and both the plasma- and whole blood
volume-corrected tracer contents were measured using
the well counter. A whole-body PET/CT examination
was performed 100 to 120 min post-administration.
[
18F]F
- (9.2 to 12.5 MBq/kg) was administered as an i.
v. bolus to three piglets to assess the bone uptake PK/
PD. Arterial blood and plasma samples were measured
using the well-counter. The animals were positioned
with a field of view as in the [
18F]FE-DTBZ-d4 dynamic
scan.
The data in this study was compared to previously
published PK/PD porcine data on non-deuterated [
18F]-
FE-DTBZ. For details on the methodologies used in this
study, see Eriksson et al. [7].
Image analysis
PET and CT images were analyzed by PMOD (PMOD
Technologies Ltd., Zürich, Switzerland). Values are
given as means ± standard error of the mean [SEM]
unless otherwise stated, and statistics are based on Stu-
dent’s t test.
Tissue volumes of interest [VOIs] and regions of
interest [ROIs] were delineated on CT images or par-
tially summed PET images. The kinetic uptake in the
cortical bone tissue for all three tracers was assessed by
generating isocontour VOIs over the lumbar vertrebral
bodies in CT images.
Estimation of tracer defluorination
Since the studies on [
18F]FE-DTBZ had been performed
previously without metabolite correction analysis, we
decided to quantify the defluorination retroactively by
kinetic modeling of the cortical bone uptake. When
modeling the PK/PD of a PET tracer, we generally study
the relationship between three different functions (Equa-
tion 1) which we can express in a vector form; the input
function [Cinput], the transfer function [HTR], and the
output function [Ctissue] were defined as follows:
Cin ⊗ HTR = Ctissue (1)
Output function
The gradual accumulation of radioactivity in the cortical
bone tissue starting around 5 min after administration
was assumed to consist entirely of [
18F]F
- uptake. It is
difficult to delineate the cortical bone structures in the
spinal column due to its relative small thickness even if
isocontour thresholding is used. Partial volume effects
[PVEs] will still yield kinetics containing contributions
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pounding this problem is the observation that the bone
marrow expresses VMAT2 and subsequently, will exhi-
b i ts o m ed e g r e eo fs p e c i f i c[
18F]FE-DTBZ and [
18F]FE-
DTBZ-d4 uptake. To reduce the contribution from non-
cortical sources, VOIs over the bone marrow were
drawn, and the associated kinetics was subtracted from
the cortical isocontour VOIs. The resulting kinetics after
this operation was assessed to describe [
18F]F
- PK/PD in
the cortical bone tissue and used as the output curve
Ctissue for the quantification of tracer defluorination.
Transfer function
Cortical bone uptake of [
18F]F
- in pigs is best described
by a two-tissue compartment model. The HTR is given
in Equation 2, where 1, 2, θ1,a n dθ2 are macro-para-
meters determined by the rate constants K1, k2, k3,a n d
k4 [18]. VT and VS denote the total and specific binding
distribution volumes, respectively:
HTR = φ1 × e−θ1×t + φ2 × e−θ2×t (2)
The [
18F]F
- HTR in the cortical bone was determined
by the kinetic modeling module PKIN for PMOD.
Input function
The Cinput of [
18F]F
- is in this specific case not created
by an instantaneous bolus, but rather from a gradual
reaction where [
18F]FE-DTBZ or [
18F]FE-DTBZ-d4 is
the substrate and [
18F]F
- is the product. The rate of
defluorination can then be expressed in a single para-
meter kdefluorination if we assume that the reaction is con-
centration-dependent and unchanging over time (or
during the time frame investigated here). Cin is then
uniquely determined from the arterial blood plasma
curve [Cp] and kdefluorination (Equation 3):
Cin = Cp × e−kdeﬂuorination×t (3)
The defluorination rate constant in plasma can then
be determined by minimizing Equation 4:
NORM(Ctissue − Cin ⊗ HTR), whereCin = Cp × e−kdeﬂuorination×t ≥ 0 (4)
All optimization was performed using MatLab 7.8.0
(MathWorks, Inc., Natick, MA, USA).
Quantification of pancreatic uptake by kinetic modeling
A one-tissue compartment model was used to estimate
the compound parameter VT as well as the tissue speci-
f i cr a t ec o n s t a n t sK1 to k2 in the pancreas. The Cp was
used as an input function, corrected for tracer metabo-
lism by defluorination parameter kdefluorination deter-
mined from cortical bone uptake. The kinetic
parameters were estimated by the PMOD modeling
module PKIN.
Results
Radiochemistry
The radiosynthesis of [
18F]FE-DTBZ-d4 was successfully
performed in two steps and based on the method by
Zhang et al. [19]. In the first step, [
18F]FEtBr-d4 was pre-
pared by a nucleophilic substitution of BrCD2CD2OTs
with [
18F]F
- in the presence of K2CO3 and Kryptofix 2.2.2.
The formed [
18F]FEtBr-d4 was isolated by distillation and
trapped directly in the DMF solution containing precursor
9-O-desmethyl-(+)-DTBZ and aqueous NaOH. The purifi-
cation of [
18F]FEtBr-d4 by distillation was effective since
any nonvolatile impurities were not co-distilling. In the
subsequent step, [
18F]FE-DTBZ-d4 was rapidly formed by
[
18F]fluoroalkylation of the desmethyl precursor. Radio-
chemical conversion in the second step was approximately
70% (Figure 2). Semi-preparative HPLC purification
(Figure 3) and SPE isolation of [
18F]FE-DTBZ-d4 gave a
radiochemically pure compound (> 98%). [
18F]FE-DTBZ-
d4 was produced in good and reproducible radiochemical
yield; 1.7 to 3.0 GBq of the pure product was obtained at a
beam current of 35 μA and a 20 to 25 min proton bom-
bardment in 100 ± 20 min. The specific radioactivities ran-
ged from 192 to 529 GBq/μmol at the end of the synthesis,
and the formulated product was radiochemically stable for
up to 5 h (purity > 98%).
LC-MS/MS analysis
To further identify the product, the ion spectrum of the
carrier of [
18F]FE-DTBZ-d4 was compared to that of the
reference compound FE-DTBZ-d4 using LC-ESI-MS/
MS-TOF. The ion spectrum of the labeled product was
identical to that of the reference compound FE-DTBZ-
d4. The labeled product [M+1]
+ has a mass-to-charge
ratio [m/z] of 356.24 with fragment ions (m/z) 338.23,
310.20, 286.18, and 201.12, and the reference FE-DTBZ-
d4 [M+1]
+ h a sam / zo f3 5 6 . 2 5w i t hf r a g m e n ti o n s
(m/z) 338.23, 310.20, 286.17, and 201.12.
In vitro homogenate saturation binding
The BPs (in femtomoles per milligram protein per nano-
Molar) in human pancreatic tissues as determined with
[
18F]FE-DTBZ-d4 are presented in Table 1. The BP was
higher in the pure islets (BPislet = 27.0 ± 8.8) compared
to the exocrine homogenates (BPexocrine =1 . 7±1 . 0 ) .
The absolute BP was lower in either tissue compared to
the non-deuterated FE-DTBZ analogue described pre-
viously (BPislet =1 1 0 . 4 ,B P exocrine =9 . 8 )[ 7 ] .H o w e v e r ,
the BPislet/BPexocrine r a t i ow a si nt h es a m er a n g e( 1 6 . 0
vs. 11.2) as the non-deuterated analogue.
[
18F]FE-DTBZ-d4 biodistribution
Accumulation in the pancreas was homogenous with no
difference in uptake in the head, body, or tail in either
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18F]FE-DTBZ-d4 via [
18F]FEtBr-d4.( a) o-DCB, 135°C, 10 min. (b) NaOH, DMF, 110°C, 5 min.
Figure 3 Chromatogram from the reversed phase semi-preparative HPLC purification of [
18F]FE-DTBZ-d4. The upper trace shows
radioactivity response, and the lower trace, absorbance response. The mobile phase system is CH3CN/10 mM of H3PO4 (15:85, v/v) at a flow rate
of 6 mL/min.
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Page 6 of 13of the subjects with an average peak uptake of SUV 2.64
shortly after administration, falling to SUV 1.8 after 90
min (Figure 4a, b). All piglets were normoglycemic
shortly after the induction of anesthesia. Other abdom-
inal tissues with notable accumulation were the liver
and spleen, with faster washout kinetics than the pan-
creas. Parts of the hepatic tracer uptake could be attrib-
uted to accumulation in the bile ducts, which drains
into the common bile duct (choledoccus) for transport
to the gallbladder or the duodenum (Figure 4c). The
drainage into the duodenum is transported via the pan-
creatic duct, which potentially could lead to an overesti-
mation of the islet and/or exocrine uptake. Since no late
(30 to 90 min) accretion was seen in the pancreas and
no release into the duodenum was detected, it is likely
that the pancreatic route of excretion was closed during
the studied time frame. The bile, containing high
amounts (SUV > 10) of tracer and metabolites, was
instead transported into the gallbladder by the cystic
duct. In two cases, significant amounts of tracer leaked
into the stomach juice (SUV 15 to 20 after 20 min).
Apart from the biological elimination through the bile
system (usually mainly lipophilic), excretion through the
kidneys, urethra, and bladder was observed (Figure 4d).
The deuteration of the tracer was designed to increase
the stability to defluorination. The spinal column verteb-
rae VOIs (containing mainly the cortical bone, but also
the trabecular bone tissue due to PVE) showed moder-
ate uptake of tracer (SUV 1.4) within the initial minutes,
but no further accumulation (Figures 4b and 5a) indicat-
ing low defluorination.
Tracer defluorination of DTBZ analogues
T h et w o - t i s s u ec o m p a r t m e n tHTR for [
18F]F
- into the
cortical spinal bone was consistent over all three piglets,
predicting large accumulation in the specific binding
compartment (k3 = 0.42 ± 0.04 min
-1) with close to irre-
versible kinetics (k4 = 0.0058 ± 0.0004 min
-1;T a b l e2 ) .
A l m o s tt h ee n t i r et i s s u eu p t a k ei sp r e d i c t e dt ob e
attributed to the specific compartment (VS/VT = 0.99),
with less than 1% of the signal coming from the nonspe-
cific or free tracer. The parameter value ratios are com-
parable to those found previously in a porcine model
[20].
Translating the rate constants into biological terms
yields a consistent image where the fluoride is distribu-
ted into the bone tissue by regular blood perfusion and
is incorporated in the cortical bone through mineraliza-
tion by binding to apatite.
The gradual dynamic defluorination of [
18F]FE-DTBZ-
d4 and [
18F]FE-DTBZ in plasma was retrospectively deter-
mined from the dynamic cortical bone uptake (Figure 6),
and the cortical HTR was acquired from [
18F]F
- data. The
defluorination rate constant kdefluorination (Table 3) was
significantly lower for the deuterated [
18F]FE-DTBZ-d4
(kdefluorination = 0.0016 ± 0.0007 min
-1) compared to the
non-deuterated [
18F]FE-DTBZ (kdefluorination = 0.012 ±
0.002 min
-1; p < 0.05). Alternatively, the defluorination can
be expressed as the half-life stability which corresponds to
over 6 h for the deuterated tracer compared to just over
1 h for the non-deuterated version.
Quantification of pancreatic uptake
Table 4 presents the best fit one-tissue compartment
model parameters for [
18F]FE-DTBZ-d4 and [
18F]FE-
DTBZ. The two rate constants were decreased after deu-
teration (p(K1) = 0.054, p(k2)<0 . 0 5 ) ,b u tt h em a c r o -
parameter VT was unchanged (p =0 . 2 7 ) .T h e r ei sn o
difference in the specific VMAT2 binding in pancreas
uptake even though more native [
18F]FE-DTBZ-d4 is
available in the blood plasma. The rate constants repre-
sent a higher influx and efflux of the free tracer but
have no net accumulation.
Discussion
In this study, we modified the VMAT2 PET ligand
[
18F]FE-DTBZ by deuteration to reduce the rate of
defluorination. The fluoroethoxy group of [
18F]FE-
DTBZ can be defluorinated in vivo by an initial enzy-
matic attack at a C-H bond leading to the decomposi-
tion of the entire radionuclide carrying the ethyl
group. The observed uptake of radioactivity in the cor-
tical bone tissue in the previous study of Eriksson et
al.[7] suggested that [
18F]FE-DTBZ might have been
defluorinated extensively in vivo by this mechanism.
To reduce the rate of defluorination, we investigated if
substituting hydrogen for deuterium would increase
radioligand stability through a primary isotope effect.
It is reported that the cleavage rate of the C-H bond is
6.7 times faster than that of the C-D bond at 25°C
[21], and this breakage of the C-H bond is considered
to be the rate-determining step in defluorination [22].
There are several examples of PET ligands in the
Table 1 Total receptor BP determined in either endocrine
or exocrine tissue homogenates (n =4 )
BP = Bmax/Kd
a
Tissue batch Islet Exocrine
1 29.9 1.0
2 50.1 0.9
3 19.0 0.3
4 9.1 4.5
Average 27.9 1.7
SEM 8.8 1.0
aBP was significantly different in the islet and exocrine homogenates (islet/
exocrine = 16.0, p < 0.05). For reference, the BP values for the non-deuterated
analogue in the islet and exocrine homogenates were 110.4 and 9.8,
respectively. BP, binding potential; SEM, standard error of the mean.
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Page 7 of 13literature where deuterium substitution has improved
the in vivo metabolic stability [14,15,23,24].
T h em a i nd i f f e r e n c ei nt i s s u eP K / P Db e t w e e nt h e
deuterated and non-deuterated DTBZ analogues
occurred in the bone tissue (Figures 5a, b and 6). The
bone tissue consists of the cortical bone (the dense bone
containing hydroxylapatite) and the trabecular bone (a
more porous material containing blood vessels and the
bone marrow), and these can be difficult to separate in
VOIs, especially in the spinal column where the cortical
fraction is relatively low (Figure 7). Fast uptake of the
tracer in the vertebrae bone tissue was seen during the
first 5 min for both [
18F]FE-DTBZ-d4 and [
18F]FE-
DTBZ. During the remainder of the scan, there was a
close to linear accretion for [
18F]FE-DTBZ, which was
almost completely absent after administration of [
18F]
FE-DTBZ-d4, consistent with the previous work of
Schou et al. [14]. We hypothesized that the uptake ‘pla-
teau’ of SUV 1 to 1.5 for both tracers consisted of both
nonspecific binding as well as specific binding to
VMAT2 expressed by cells in the bone marrow [25],
while the gradual accumulation was due to irreversible
[
18F]F
- binding to apatite in the cortical bone. The esti-
mated defluorination rate constant kdefluorination differed
significantly between the two deuterated and non-deut-
erated DTBZ analogues.
Figure 4 Transaxial PET/CT fusion image, average dynamic uptake of [
18F]FE-DTBZ-d4, and tracer excretion. Delineation of the pancreas
(red), spleen (green), and parts of the anterior and posterior hepatic segments (black) exemplified on a transaxial PET/CT fusion image (a). The
average dynamic uptake of [
18F]FE-DTBZ-d4 in the pancreas and other abdominal tissues from four different piglets (b). Excretion through the
biliary system is the fate of a majority of the tracer and its metabolites (c), but there is also an elimination of the tracer by urine (d).
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and delineation of the pancreatic tissue contain many
potential difficulties, regardless on the animal model
studied. Mice and rat models have stretched, diffuse
pancreata which can be very difficult to delineate and
separate from neighboring tissues, especially without the
aid of CT. This is a lesser problem in a large animal
model as the pig, which is one of the reasons for the
choice of the model in this study. Other difficulties arise
from the proximity of high or moderate-uptake regions
such as the kidney cortex, the spleen, and potentially,
the duodenum. The pancreas can usually be visualized
on a few transaxial CT slices (depending on the orienta-
tion) without oral contrast administration, but the PET
kinetics can still be affected by PVEs (where voxels
contain contributions from neighboring tissues). To
avoid PVE, we modified the CT-guided pancreatic deli-
neation by studying the kinetics of the neighboring tis-
sues, the kidney, the cortex, and the spleen. The kidney
cortex was avoided by studying early-time summations,
and the splenic uptake was separable from the pancrea-
tic uptake due to the washout being very rapid during
later frames. Further analysis of kinetics using techni-
ques such as masked volume-wise principal compart-
ment analysis could further aid pancreatic delineation.
The tracer-receptor interactions of [
18F]FE-DTBZ-d4
were seemingly altered by the deuteration although the
difference between the two functional groups of O-
CD2CD2F (deuterated) and O-CH2CH2F (non-deuter-
ated) is too small to change the molecular similarity and
Figure 5 Three-dimensional maximum intensity projection. The figure shows 3-D maximum intensity projection 90 min after administration
of (a)[
18F]FE-DTBZ-d4; low accumulation in bone structures indicates low levels of free [
18F]F
- and (b) non-deuterated [
18F]FE-DTBZ; high
accumulation in bone structures is due to higher levels of free [
18F]F
-. Colors indicate SUV 0 (black) to SUV 30 (white).
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Page 9 of 13bioisoteric properties. However, BP is a composite con-
stant determined by the ratio between Bmax and Kd.
Therefore, BP can be altered without any change in
receptor affinity (Kd). By contrast, Bmax can be affected
by several factors such as rec e p t o re x p r e s s i o ni ne a c h
individual islet/exocrine batch, the availability of recep-
tors due to homogenization, and the determination of
the total amount of protein content for individual cell
cultures. Most likely, the decreased BP represents differ-
ences in islet viability and VMAT2 expression between
batches. If the comparison between the tracers were
performed on identical islet batches or on a larger
group size, we postulate that the difference in the mea-
sured BP would decrease. The [
18F]FE-DTBZ-d4 BP was
decreased both in the endocrine and exocrine tissues
compared to that of [
18F]FE-DTBZ. Most importantly,
the 16-fold BPislet/BPexocrine ratio shows that the radio-
tracer, [
18F]FE-DTBZ-d4, has similar characteristics for
discriminating between the islet and exocrine tissues as
the non-deuterated compound, but also a large exocrine
nonspecific signal will still be present in the native pan-
creas in vivo.
Conclusion
In this study, deuterium-substituted [
18F]FE-DTBZ-d4
was designed, synthesized, and evaluated in vitro and in
Table 2 Best fit parameters for describing the HTR for
[
18F]F
- PK/PD in the cortical spinal bone
Parameter Unit Pig 1 Pig 2 Pig 3 Average SEM
K1
a (cc/min)/cc 0.71 0.44 0.56 0.57 0.08
k2
a 1/min 1.27 1.78 1.57 1.54 0.15
k3
a 1/min 0.39 0.5 0.38 0.42 0.04
k4
a 1/min 0.0061 0.0062 0.0051 0.0058 0.0004
VS
b cc/cc 35.9 19.8 26.9 27.53 4.66
VT
b cc/cc 36.4 20.1 27.2 27.9 4.72
VS/VT 0.99 0.99 0.99 0.99 0
Plasma delay s 25.6 23.5 27.9 25.67 1.27
Chi-square fit 0.43 0.41 0.29 0.38 0.04
aRepresent the rate constants describing tracer flux between the blood
plasma and the free/nonspecific tissue compartment (K1 and k2) as well as the
flux into and out of the specific binding compartment (k3 and k4).
bThe
distribution volumes of the different compartments are expressed by Vs
(specific bound tracer) and VT (specific bound, nonspecific bound, and free
tracers). SEM, standard error of the mean.
Figure 6 Uptake of the respective DTBZ analogue in the cortical bone tissue. The pure cortical uptake was estimated by reducing the
influence of partial volume effects due to the non-cortical bone tissue and vascular contributions. This was done by subtracting the trabecular
bone uptake from the total uptake in cortical VOIs in the body of the thoracic and lumbar vertebrae in the lower spinal column.
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Page 10 of 13Table 4 One-tissue compartment model parameters using defluorination-corrected plasma input curves
Parameter Unit Exp 1 Exp 2 Exp 3 Average SEM
[
18F]FE-DTBZ
K1 (cc/min)/cc 0.27 0.30 0.20 0.26 0.03
k2 1/min 0.08 0.07 0.04 0.064 0.01
VT
b cc/cc 3.39 4.47 4.65 4.17 0.39
Chi-square fit 29.2 19.1 13.3
[
18F]FE-DTBZ-d4
a
K1 (cc/min)/cc 0.65 1.09 1.13 0.36 0.81 0.18
k2 1/min 0.32 0.25 0.37 0.10 0.26 0.06
VT
b cc/cc 2.05 4.39 3.06 3.64 3.69 0.49
Chi-square fit 6.8 4.0 3.7 2.7
aResults for [
18F]FE-DTBZ-d4 are compared to a reanalysis of [
18F]FE-DTBZ.
bThe total distribution volume (VT) is calculated from the rate constant ratio K1/k2. VT is
not affected by deuterization even though both K1 and k2 are increased. SEM, standard error of the mean.
Table 3 Defluorination rate in piglets between the deuterated and non-deuterated FE-DTBZ analogues (p < 0.05)
Parameter Unit Exp 1 Exp 2 Exp 3 Average SEM
[
18F]FE-DTBZ
kdefluorination
a 1/min 0.015 0.0079 0.01214 0.012 0.002
t1/2 min 46.2 87.7 57.1 63.4
RSS 0.34 1.03 0.65
[
18F]FE-DTBZ-d4
kdefluorination
a 1/min 0.0016 0.00042 0.0035 0.00088 0.0016 0.0007
t1/2 min 438.7 1650.4 197.5 787.7 433.9
RSS 0.50 0.14 0.16 0.16
aThe rate constant kdefluorination was almost 7.5 times lower after deuteration (0.0016 ± 0.0007 min
-1 vs. 0.012 ± 0.002 min
-1), resulting in an increased stability
half-life (more than 6 h, up from 1 h). t1/2, half-life; RSS, regression sum of squares; SEM, standard error of the mean.
Figure 7 Computer-assisted delineation of the cortical (white) and trabecular (black) bone tissues in the vertebrae. Isocontour ROIs were
generated by thresholding on CT images. In this example, the cortical and trabecular ROIs have average densities of 391 and 255 HU, respectively.
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18F]FE-
DTBZ-d4 was synthesized by alkylation of the 9-O-des-
methyl-(+)-DTBZ precursor via [
18F]FEtBr-d4 in high
radiochemical yield and purity. [
18F]FE-DTBZ-d4 gained
increased stability against defluorination in vivo com-
pared to [
18F]FE-DTBZ and retained a similar BPislet/
BPexocrine ratio. These characteristics are especially
important when considering the study of VMAT2 dense
tissues in proximity to cortical bone structures, as in the
case of intramuscular islet transplantation in preclinical
or clinical settings. Although the tracer specificity for
beta cells is insufficient for the imaging of endogenous
pancreatic islets, it is a prime candidate for future pre-
clinical and clinical studies on focal clusters of beta
cells, such as in intramuscular islet grafts. Our results
have also demonstrated that the deuterium substitution
is an effective tool for improving the properties of the
corresponding non-deuterated PET radioligand by redu-
cing their in vivo metabolic rates.
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